title: The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats.
abstract: The long-term use of levodopa as a pharmacotherapy for Parkinson's disease is limited by the development of levodopa-induced dyskinesias. However, recent studies have suggested that pharmacological targeting of the endocannabinoid system may provide a viable adjunct to suppress these motor side effects. Thus, this study sought to determine the effect of pharmacologically activating or blocking endocannabinoid signalling on levodopa-induced dyskinesias in a rat model. Male Sprague-Dawley rats with 6-hydroxydopamine lesions were made dyskinetic by 6 weeks of daily levodopa injections (10mg/kg s.c.). Rats that developed stable abnormal involuntary movements (AIMs) received acute injections of the cannabinoid receptor agonist, HU210 (0.0, 0.5, 5.0, and 50.0 μg/kg i.p.), or the CB(1) receptor antagonist/inverse agonist, AM251 (0.0 and 3.0mg/kg i.p.), whereas rats that did not develop stable AIMs received injections of the CB(1) receptor antagonist/inverse agonist, rimonabant (0.0 and 3.0mg/kg i.p.), for 18 days. In the dyskinetic rats, the highest dose of HU210 significantly reduced certain subtypes of AIMs but it also impaired normal motor functioning, while AM251 had no effect on AIMs. In the non-dyskinetic rats, rimonabant precipitated certain subtypes of AIMs. Overall, this study demonstrates that the anti-dyskinetic effects of cannabinoid receptor agonists may not be dissociable from their motor suppressant effects thereby limiting their potential usefulness for treating established dyskinesias in parkinsonism. However, it is intriguing that blockade of endocannabinoid-CB(1) signalling can unmask levodopa-induced AIMs, and this finding suggests that endocannabinoid tone may confer protection against the development of levodopa-induced dyskinesias.
authors.affiliation: Department of Pharmacology & Therapeutics, National University of Ireland, Galway, Ireland. s.walsh12@nuigalway.ie
authors.forename: Sinéad
authors.initials: S
authors.lastname: Walsh
authors.forename: Adrienne M
authors.initials: AM
authors.lastname: Gorman
authors.forename: David P
authors.initials: DP
authors.lastname: Finn
authors.forename: Eilís
authors.initials: E
authors.lastname: Dowd
mesh_terms: D000818:Animals; D000978:Antiparkinson Agents / Q000009:adverse effects; D004195:Disease Models, Animal; D013759:Dronabinol / Q000031:analogs & derivatives* / Q000494:pharmacology; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000517:prevention & control; D007980:Levodopa / Q000009:adverse effects*; D008297:Male; D020734:Parkinsonian Disorders / Q000188:drug therapy*; D010880:Piperidines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D043884:Receptor, Cannabinoid, CB1 / Q000819:agonists* / Q000037:antagonists & inhibitors / Q000378:metabolism; D000077285:Rimonabant
chemical_list: D000978:Antiparkinson Agents; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; C103505:AM 251; D007980:Levodopa; D013759:Dronabinol; C062018:HU 211; D000077285:Rimonabant